Aion Therapeutic Inc.
ANTCF
$0.012
-$0.003-20.00%
| 01/31/2024 | 10/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 41.52% | 22.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 68.87% | 22.72% | |||
| Operating Income | 14.08% | -22.72% | |||
| Income Before Tax | -109.51% | 30.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -109.51% | 30.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -109.51% | 30.09% | |||
| EBIT | 14.08% | -22.72% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -28.57% | 36.36% | |||
| Normalized Basic EPS | -50.00% | 42.86% | |||
| EPS Diluted | -28.57% | 36.36% | |||
| Normalized Diluted EPS | -50.00% | 42.86% | |||
| Average Basic Shares Outstanding | 65.98% | 12.74% | |||
| Average Diluted Shares Outstanding | 65.98% | 12.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
